Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase II clinical trial, which tests the safety and effectiveness of
an investigational drug Natalizumab in treating Acute Graft-Versus-Host Disease (GVHD) in the
Gastrointestinal (GI) Tract.